Literature DB >> 28384659

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.

Todd C Knepper1, Morganna L Freeman2, Geoffrey T Gibney3, Howard L McLeod4, Jeffery S Russell5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28384659     DOI： 10.1001/jamadermatol.2017.0187

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  2 in total

Review 1.  Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.

Authors:  M Nikanjam; P R Cohen; S Kato; J K Sicklick; R Kurzrock
Journal:  Ann Oncol       Date:  2018-11-01       Impact factor: 32.976

2.  Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.

Authors:  Philip R Cohen; Shumei Kato; Aaron M Goodman; Sadakatsu Ikeda; Razelle Kurzrock
Journal:  Int J Mol Sci       Date:  2017-07-31       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.